Humalog®

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

HUMALOG® (insulin lispro): Changing From Other Mealtime Insulin Products

Dose adjustment may be needed when transitioning from another insulin to Humalog (insulin lispro).

Dose adjustment may be needed when transitioning from another insulin to Humalog® (insulin lispro). Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased (Humalog Package Insert, 2015).

Enclosed Prescribing Information

HUMALOG® (insulin lispro injection), for subcutaneous or intravenous use, Lilly

The published reference below is available upon request by contacting 1-800-LillyRx.

Reference

Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

Date of Last Review: March 18, 2017

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical